TSE:TRL - Trilogy International Partners Stock Price, Forecast & News

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

Trilogy International Partners declared an annual dividend on Monday, April 15th. Shareholders of record on Monday, May 6th will be given a dividend of 0.02 per share on Monday, May 6th. This represents a yield of 0.86%. The ex-dividend date of this dividend is Monday, April 15th. View Trilogy International Partners' Dividend History.

Trilogy International Partners is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Trilogy International Partners.

2 brokerages have issued 1-year price targets for Trilogy International Partners' stock. Their forecasts range from C$3.25 to C$3.50. On average, they expect Trilogy International Partners' share price to reach C$3.38 in the next year. This suggests a possible upside of 109.6% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.

News coverage about TRL stock has trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trilogy International Partners earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Trilogy International Partners.

Some companies that are related to Trilogy International Partners include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), NanoViricides (NNVC), Pharmaxis (PXS), Vita Life Sciences (VLS), Avivagen (VIV), Futura Medical (FUM), Patrys (PAB), Antisense Therapeutics (ANP), China Pharma (CPHI), Sareum (SAR), Cathay International (CTI) and N4 Pharma (N4P).

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Merck & Co., Inc. (MRK), Millicom International Cellular (MIICF), Oncolytics Biotech (ONCYF), Emera (EMA), Glacier Bancorp (GBCI), Fibrocell Science (FCSC), CytomX Therapeutics (CTMX), CSX (CSX) and Check Cap (CHEK).

Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

One share of TRL stock can currently be purchased for approximately C$1.61.

Trilogy International Partners has a market capitalization of C$93.42 million and generates C$734.77 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe.View Additional Information About Trilogy International Partners.

The official website for Trilogy International Partners is http://www.trilogy-international.co.../.

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.